Overview
Overview
Sermorelin is a synthetic growth hormone–releasing hormone (GHRH) analog that stimulates endogenous pituitary GH secretion[1]. Originally approved for pediatric growth hormone deficiency, it is studied for adult off‑label use to support physiologic GH output and IGF‑1 levels[2]. This educational protocol presents a once‑daily subcutaneous approach administered at bedtime to align with natural nocturnal GH release[3]. Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration. Typ
- Category
- Growth Hormone
- Routes
- subcutaneous
Mechanism
Sermorelin
Mechanism of action
Mechanism of action
Sermorelin works by talking to the pituitary gland , a small gland at the base of the brain that makes growth hormone (GH). The pituitary normally listens for a signal from the brain called GHRH (growth hormone-releasing hormone). When GHRH shows up, the pituitary releases a burst of GH. Sermorelin is a short copy of GHRH. The natural hormone is 44 amino acids long. Sermorelin uses only the first 29. Despite being shorter, the 29-amino-acid version still fits the GHRH receptor and still triggers a GH pulse. That is the main mechanism. The body has a natural "off switch" hormone called somatostatin . When GH levels climb too high, somatostatin steps in and quiets the pituitary back down. Because sermorelin works through the body's own GHRH pathway, this off switch stays active. GH levels rise in natural pulses rather than staying flat and elevated. This is the key difference from direct GH injections. With direct GH, the dose you inject is the dose you get - the off switch is bypassed. With sermorelin, the brake is still on, so the body protects itself from very high GH levels even at higher sermorelin doses. Healthy growth hormone in the body is pulsatile - it rises and falls in waves, with the biggest waves during early sleep. Sermorelin's short half-life (11-12 minutes) actually fits this pattern well. It nudges the pituitary into making a pulse, then clears out fast, leaving the body's own rhythm in place.
Key research findings
- 01
Synthetic GHRH(1-29)NH2 — the N-terminal 29 amino acids of human GHRH, the shortest fully bioactive fragment; acts as a GHRH-receptor agonist on pituitary somatotrophs to stimulate endogenous GH release (endocrinology; human study).
- 02
Native (unmodified) sequence with a short plasma half-life (minutes); less enzymatically stable than the tetrasubstituted GRF analogs such as CJC-1295 / modified GRF 1-29 (pharmacology).
- 03
Because it stimulates the body's own pulsatile GH release, the literature framed it as more physiologic than administering exogenous GH (mechanistic framing; human study).
- 04
Was an approved product (Geref, Serono) historically used in clinical research as a GHRH-stimulation (GH-axis) test agent; the FDA's Federal Register determination states it was NOT withdrawn from sale for reasons of safety or effectiveness — i.e., the discontinuation was commercial (regulatory history).
Primary source: FDA-era diagnostic program (1990): Single-dose IV sermorelin produced rapid, specific GH release in healthy children and a blunted response in GH-deficient children. This is the data that supported sermorelin's diagnostic FDA approval. FDA-era pediatric treatment program (1997): Children with growth hormone deficiency received nightly subQ sermorelin at 0.2-0.3 mg/day. Trials showed significant increases in GH release and growth velocity at 6 months, with efficacy reported through 36 months. Pharmacokinetics (Ishida et al., 2020): Pooled PK data showed a half-life of about 11-12 minutes after either IV or subQ dosing, plasma clearance of 2.4-2.8 L/min, and rapid time-to-peak after subcutaneous injection. Adult-context review (Walker, 2006): Walker's review in Clinical Interventions in Aging discussed sermorelin for adult GH insufficiency, highlighting the pituitary-supportive and feedback-regulated nature of GHRH stimulation versus direct GH replacement. Modern adult RCT data: Large modern randomized controlled trials in adults are limited after the 2008 commercial discontinuation. Current adult dosing rests on practitioner experience and published reviews rather than fresh Phase 3 trials.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Protocol Reference
Protocol reference
Commonly cited research range: 200–500 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2 (Initiation)
100 mcg
Weeks 3–4 (Standard)
200 mcg
Weeks 5–8 (Optimization)
300 mcg
Week 9+ (Elevated)
400-500 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 (Initiation) | 100 mcg | 4 units (0.04 mL) |
| Weeks 3–4 (Standard) | 200 mcg | 8 units (0.08 mL) |
| Weeks 5–8 (Optimization) | 300 mcg | 12 units (0.12 mL) |
| Week 9+ (Elevated) | 400-500 mcg | 16–20 units (0.16–0.20 mL) |
Titration protocol
- Weeks 1–2 (Initiation)Start100 mcg
Nightly subcutaneous, 30–60 minutes before bed on an empty stomach (wait 60–90 minutes after the last meal). Rotate injection sites.
- Weeks 3–4 (Standard)Build200 mcg
Nightly subcutaneous, same pre-bed timing. Scheduling models: 7 nights per week, or 5 on / 2 off (Sunday–Thursday on, Friday–Saturday off).
- Weeks 5–8 (Optimization)Build300 mcg
Nightly subcutaneous. Hold this step for the full four weeks; lab draws are commonly repeated at the 6-week point.
- Week 9+ (Elevated)Maintenance400-500 mcg
Nightly subcutaneous. The upper end of the range is an optional step above 300 mcg. A missed dose is skipped and resumed the next night, never doubled. Typical run is 3–6 months at the target dose; a reconstituted vial is replaced roughly every 28 days.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Wipe the vial stopper: remove the plastic cap, wipe the rubber stopper with an alcohol swab, and let it dry.
- 02🧴Draw 2 mL bacteriostatic water into a sterile syringe — this 5 mg vial yields 2.5 mg/mL.
- 03💉Inject against the wall: insert the needle at an angle and aim the water at the inside wall of the vial, not directly onto the powder.
- 04💧Let it run down: let the water flow gently down the side of the vial; do not spray or force it.
- 05🔄Mix slowly: remove the syringe and roll the vial between your palms for 30–60 seconds until fully dissolved; do not shake.
- 06🏷️Inspect: the solution should be clear and colorless; discard if cloudy, discolored, or particulate.
- 07❄️Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at 2–8 °C (36–46 °F) in dry, dark conditions [2] . Do not freeze dry powder; check expiration date.
Refrigerate at 2–8 °C (36–46 °F) [4] ; do not freeze mixed solution [4] . Use within 10–14 days when using bacteriostatic water (multi‑dose vial).
Allow vials to reach room temperature before reconstituting to aid dissolution; inspect solution before each use (should be clear and colorless) [2] .
swab stopper with alcohol before each draw; use new sterile needle and syringe per injection [2] .
Clinical Evidence
Clinical evidence
Research demonstrates restoration of youthful GH patterns. Improves sleep quality, body composition, and recovery.
FDA-era diagnostic program (1990): Single-dose IV sermorelin produced rapid, specific GH release in healthy children and a blunted response in GH-deficient children. This is the data that supported sermorelin's diagnostic FDA approval. FDA-era pediatric treatment program (1997): Children with growth hormone deficiency received nightly subQ sermorelin at 0.2-0.3 mg/day. Trials showed significant increases in GH release and growth velocity at 6 months, with efficacy reported through 36 months. Pharmacokinetics (Ishida et al., 2020): Pooled PK data showed a half-life of about 11-12 minutes after either IV or subQ dosing, plasma clearance of 2.4-2.8 L/min, and rapid time-to-peak after subcutaneous injection. Adult-context review (Walker, 2006): Walker's review in Clinical Interventions in Aging discussed sermorelin for adult GH insufficiency, highlighting the pituitary-supportive and feedback-regulated nature of GHRH stimulation versus direct GH replacement. Modern adult RCT data: Large modern randomized controlled trials in adults are limited after the 2008 commercial discontinuation. Current adult dosing rests on practitioner experience and published reviews rather than fresh Phase 3 trials.
- 01Synthetic GHRH(1-29)NH2 — the N-terminal 29 amino acids of human GHRH, the shortest fully bioactive fragment; acts as a GHRH-receptor agonist on pituitary somatotrophs to stimulate endogenous GH release (endocrinology; human study).
- 02Native (unmodified) sequence with a short plasma half-life (minutes); less enzymatically stable than the tetrasubstituted GRF analogs such as CJC-1295 / modified GRF 1-29 (pharmacology).
- 03Because it stimulates the body's own pulsatile GH release, the literature framed it as more physiologic than administering exogenous GH (mechanistic framing; human study).
- 04Was an approved product (Geref, Serono) historically used in clinical research as a GHRH-stimulation (GH-axis) test agent; the FDA's Federal Register determination states it was NOT withdrawn from sale for reasons of safety or effectiveness — i.e., the discontinuation was commercial (regulatory history).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Sermorelin.
- 01PubMed — Prakash & Goa (1999): Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (pediatric GHD; 30 µg/kg SC nightly; 6–12 month trials) View Sourceet al. (1999)
- 02RxList — Sermorelin Acetate Injection Monograph: dosing (0.2–0.3 mg SC qHS adult off‑label); reconstitution/storage/administration guidelines View Source
- 03PubMed — Clinical studies: bedtime SC injection leverages natural nocturnal GH pulse; once‑daily nightly dosing yielded significant growth improvements in pediatric GHD over 6–12 months View Source
- 04Mayo Clinic — Sermorelin (injection route) – Proper Use and Storage: refrigerate reconstituted solution at 2–8 °C (36–46 °F); do not freeze; use within recommended period View Source
- 05RxList — Sermorelin Acetate Prescribing Information: adverse effects (injection‑site reactions ~17%; rare headache/flushing <1%); subclinical hypothyroidism ~6.5%; thyroid monitoring recommended View Source
- 06PubMed — Sermorelin mechanism: stimulates endogenous pulsatile GH via GHRH receptors; preserves physiologic feedback loops (somatostatin/IGF‑1 negative feedback); reduces overdose risk vs. exogenous GH View Source
- 07Johns Hopkins Arthritis Center — How to Give a Subcutaneous Injection: site selection (abdomen/thigh/arm); rotation guidelines; 45–90° angle; pinch technique; no aspiration; disposal in sharps container View Source
- 08CDC — Vaccine administration: subcutaneous route technique (45–90° angle; site prep; no aspiration for SC injections) View Source
- 09PubMed — Sermorelin dosing considerations: higher doses (up to 500 µg daily) used in research for greater IGF‑1 response in adults; aging/obesity associated with blunted GH release; cautious titration recommended View Source
- 10RxList — Sermorelin treatment duration: pediatric studies 6–12 months daily therapy with sustained effect; some continued up to 36 months; adult off‑label cycles typically 3–6 months to evaluate efficacy View Source
- 11NCBI Bookshelf — Best practices for parenteral injections: aseptic technique, preparation, administration guidelines View Source
- 12RxList — Sermorelin safety profile: no serious acromegaly or hypoglycemia at recommended dosages; built‑in negative feedback prevents excessive GH/IGF‑1; FDA‑approved (as Geref) for decades with good safety record View Source
- 13Pure Lab Peptides — Sermorelin 5 mg product page: high‑purity research‑grade peptide with batch COAs; quality and documentation standards View Source
Observed Effects
Observed effects in cited research
Common Observed Effects
- Injection-site reactions (about 1 in 6 participants, roughly 17%): pain, swelling, or redness at the injection site. Usually mild, usually went away on their own. Only 3 of 350 patients stopped treatment because of them.
Less Common Observed Effects (each under 1%)
- Headache
- Facial flushing
- Difficulty swallowing (dysphagia)
- Dizziness
- Restlessness or hyperactivity
- Drowsiness
- Changes in taste
- Hives (urticaria)
- Nausea or vomiting (more often with IV diagnostic use than nightly subQ)
Things to Monitor
- Antibody development. About 70% of FDA-era trial participants developed anti-GRF antibodies at least once during treatment. The label noted that these antibodies did not appear to meaningfully reduce sermorelin's effectiveness or cause specific reactions in most participants.
- Hypothyroidism. About 6.5% of trial participants developed hypothyroidism. Untreated hypothyroidism reduces the body's response to GH stimulation, so baseline and follow-up thyroid labs are standard practice.
- Allergic reactions. Like any injected peptide, sermorelin can cause local or, rarely, systemic allergic reactions. Stop and seek medical attention for swelling of the face, mouth, or throat, trouble breathing, or widespread hives.
Lower-Risk Profile Compared to Direct GH
- Because sermorelin works through the body's own feedback system, the risk of pushing GH or IGF-1 too high is built-in lower than with direct recombinant GH injections. Clinical data also showed no significant abuse or dependence potential.
Research Considerations
Research considerations
Research peptide. Effects are milder than direct GH. Consult healthcare provider.
- Known allergy to sermorelin or any of the ingredients in the formulation.
- Pregnancy or breastfeeding. The FDA-era label flagged sermorelin as Pregnancy Category C. There are no controlled studies in pregnant women, and it is unknown whether sermorelin passes into breast milk.
- Active cancer. GH and IGF-1 can act as growth signals on existing cells. Most protocols screen for active malignancy before starting.
- Growth hormone deficiency from an intracranial lesion - the FDA-era label specifically said these patients were not studied and were not recommended for sermorelin therapy.
- Untreated hypothyroidism. This blunts the GH response and should be corrected first.
- On glucocorticoid therapy. Glucocorticoids can blunt the response to sermorelin per the FDA-era label drug interactions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Sermorelinthis | Binds to GHRH receptors to stimulate pulsatile GH release, mimicking natural patterns. Preserves feedback mechanisms. | subcutaneous | Investigational / RUO |
| Tesamorelin | Binds to GHRH receptors to stimulate endogenous GH production. Preferentially reduces abdominal fat accumulation. | subcutaneous | Investigational / RUO |
| CJC-1295 | Binds to GHRH receptors to stimulate GH release. Modified structure provides extended duration of action (up to 7 days). | subcutaneous | Investigational / RUO |
| CJC-1295 DAC | A synthetic GHRH analog with a drug-affinity-complex (DAC) modification that binds serum albumin, greatly extending half-life and producing sustained stimulation of pituitary GH release. | subcutaneous | Investigational / RUO |
| CJC-1295 NO DAC | A synthetic 29-amino-acid GHRH analog (Modified GRF 1-29) that stimulates natural, pulsatile growth hormone secretion from the pituitary; without a DAC it has a short duration of action. | subcutaneous | Investigational / RUO |
| SLU-PP-332 | A synthetic pan-agonist of estrogen-related receptors (ERR alpha/beta/gamma) studied for activation of an aerobic-exercise-like gene program and increased oxidative metabolism. | — | Investigational / RUO |
| SNAP-8 | A synthetic acetylated octapeptide (an extended Argireline analog) studied for topical reduction of muscle contraction by interfering with SNARE-complex formation at the neuromuscular junction. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Common adult research-context starting guidance is 100-200 mcg subQ at bedtime for the first 1-2 weeks, then titrating to 200-300 mcg nightly. The historical FDA-era pediatric label used 0.2-0.3 mg/day. Adult protocols are typically adjusted based on response, sleep changes, and IGF-1 lab trends. This is not a dosing recommendation - work with a licensed clinician.
A common research-context setup is 3 mL of bacteriostatic water in a 10 mg vial, which gives a 3,333 mcg/mL concentration. On a U-100 insulin syringe, that produces clean whole-unit doses: 100 mcg = 3 units, 200 mcg = 6 units, 300 mcg = 9 units. For other vial sizes or water volumes, recheck with the PepPal calculator .
It depends on your vial size and how much BAC water you used. With the common 10 mg vial plus 3 mL BAC water setup, 200 mcg equals 6 units on a U-100 syringe and 300 mcg equals 9 units. For any other setup, use the calculator linked in this protocol to get the exact unit count.
Sermorelin's plasma half-life is approximately 11-12 minutes after either IV or subQ injection, per Ishida et al. (2020) and the FDA-era prescribing data. Plasma clearance is in the 2.4-2.8 L/min range. The growth hormone pulse triggered by sermorelin lasts longer than the parent peptide stays in circulation.
Sermorelin was FDA-approved in 1990 (diagnostic use) and 1997 (pediatric GH deficiency, brand name Geref). Serono Laboratories voluntarily discontinued Geref in 2008 due to manufacturing difficulties, not safety concerns. As of June 2026, there is no currently marketed FDA-approved sermorelin product. However, sermorelin still sits in FDA 503A Category 1, which means licensed compounding pharmacies can legally prepare it with a prescription.
Yes. Sermorelin remains in FDA 503A Category 1, which means licensed 503A and 503B compounding pharmacies can legally prepare it for patients with a valid prescription. This is different from most other research peptides (BPC-157, CJC-1295, ipamorelin, TB-500, and others), which sit in Category 2 and cannot be legally compounded.
Across 350 FDA-era trial patients, the most common observed effect was a mild injection-site reaction - pain, swelling, or redness - in about 1 in 6 participants. Only 3 of 350 patients discontinued because of it. Less common effects (each under 1%) included headache, flushing, dizziness, difficulty swallowing, drowsiness, and hives. About 6.5% developed hypothyroidism during trials, which is why thyroid labs are standard monitoring.
Practitioner timelines and FDA-era data line up on a similar pattern: sleep and recovery changes often appear in 2-4 weeks. Body-composition shifts and IGF-1 increases usually need 3-6 months of consistent nightly dosing. Adult-population endpoint data outside practitioner literature is limited, so individual response varies.
All three target the GHRH receptor, but they differ in half-life, dosing, and regulatory status. Sermorelin: ~12 minute half-life, nightly, 503A Category 1. Tesamorelin: ~26-38 minute half-life, daily, FDA-approved for HIV-associated lipodystrophy. CJC-1295 (DAC): ~6-8 day half-life, weekly, 503A Category 2 (cannot be legally compounded). See the Tesamorelin protocol and CJC-1295 (DAC) protocol for full details.
Most research-context protocols use sermorelin 30-60 minutes before bed on an empty stomach. The body's biggest natural growth hormone pulse happens during early sleep, and bedtime dosing rides along with that pulse. Eating raises insulin, which blunts the GH response, so most protocols wait 60-90 minutes after the last meal before injecting.
Common research-channel sermorelin vial sizes include 2 mg, 5 mg, 9 mg, 10 mg, and 15 mg lyophilized formats. The 10 mg vial is widely available from current compounded and research suppliers. Smaller vials (2 mg, 5 mg) give the cleanest whole-unit syringe math. Larger vials last longer once reconstituted - but remember the 28-day reconstituted-solution shelf life.
Store reconstituted sermorelin upright in the refrigerator at 2-8°C (36-46°F), protect from light, and use within 28 days. Do not freeze reconstituted sermorelin. Discard if the solution is cloudy, discolored, or has any visible particles. Brief room-temperature windows (such as travel) are usually fine, but get it back into refrigeration as soon as possible.
Community protocols often discuss pairing sermorelin (a GHRH analogue) with ipamorelin (a GH secretagogue/GHRP) at bedtime to recruit both signaling pathways. Direct stack-specific clinical trial evidence is limited, and adding compounds increases the safety and quality-control surface area. Read the PepPal Peptide Stacking 101 guide before combining compounds.
No. This is an educational research reference. It summarizes published FDA-era data, pharmacokinetic literature, and practitioner-derived protocol structures so you have a clear starting point for a conversation with a licensed clinician. It is not a treatment plan and does not replace medical guidance.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.